#USA #Nashville #Petauri #Franklin Consulting #HEOR

Petauri's Strategic Acquisition of Franklin Pharmaceutical Consulting

In a significant move to enhance its market access and health economics capabilities, Petauri, a dedicated pharmaceutical services platform, has announced the acquisition of Franklin Pharmaceutical Consulting (FPC). This strategic acquisition marks a pivotal step in solidifying Petauri's position as a leader in communicating product value and supporting life sciences companies amidst complex reimbursement environments.

Strengthening Capabilities

Franklin Pharmaceutical Consulting specializes in health economics and outcomes research (HEOR), real-world evidence (RWE), and market access consultancy. With years of experience, FPC has consistently provided strategic and tactical support to medical and market access entities throughout various product life cycles. Their proven expertise in developing HEOR and RWE strategies, as well as payer-focused communication tools, positions them as an invaluable addition to Petauri’s offerings.

Dan Renick, CEO of Petauri, remarked on the acquisition’s significance:

"Franklin Pharmaceutical Consulting is an outstanding addition to Petauri and a natural extension of our vision for Petauri Evidence. FPC's expertise in translating HEOR and market access evidence into practical strategies will enhance our capabilities and better serve our clients."

With FPC now as part of Petauri's team, they aim to deliver comprehensive solutions that aid clients from evidence planning through commercialization and life cycle management.

The Role of Franklin Pharmaceutical Consulting

Founded by Meg Franklin, PharmD, PhD, FPC has earned a strong reputation in the industry, known for its senior-level expertise and tailored solutions. Meg expressed her enthusiasm about joining Petauri:

"We are excited to join the Petauri team and expand the global capabilities available to our clients while maintaining the scientific rigor, collaboration, and hands-on partnership they value."

As the newly appointed President of Petauri Evidence US, Dr. Franklin is set to lead this transition, ensuring continuity in service delivery and excellence.

Furthermore, Joette Gdovin, PhD, MPA, a partner at FPC, has taken on an executive role within Petauri as EVP, Evidence Value. She emphasized the importance of connecting evidence generation with value communication:

"Together with Petauri, we will connect evidence generation, value communication, and market access strategies from the start, helping clients reduce barriers and secure access to meaningful treatment options for patients."

Petauri's Vision and Future

Petauri, based in Nashville, Tennessee, aims to revolutionize pharmaceutical services by combining various best-in-class companies, creating a multidisciplinary platform that improves patient outcomes. Since its inception in 2023, Petauri has made strides by launching Petauri Advisors and integrating multiple firms such as The Kinetix Group and Mtech Access into its offerings, all aimed at enhancing life sciences, scientific communications, and market access.

Petauri utilizes a wide array of innovative solutions designed to expedite patient access to vital healthcare. With an investment of over $250 million from Oak Hill Capital, Petauri is set to continue expanding, fostering an environment ripe for innovation in the life sciences sector.

For further updates and information about Petauri’s services, visit www.petauri.com.

By expanding its capabilities through strategic acquisitions like that of Franklin Pharmaceutical Consulting, Petauri is poised to play a transformative role in improving access to innovative medical treatments and enhancing overall patient care in the pharmaceutical landscape.